Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, SVY, LIC, TRI, PSF, FVT

Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan


SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials in Japan. The former specialises in clinical trial site recruitment and retention and project management solutions, while the latter operates a cutting-edge real-time health insights exchange platform.

Mr Taketeru Inokawa (left) and Dr Huren Sivaraj (right) during the MOU signing ceremony in Singapore.

The collaboration will extend to Oncoshot's strategic contract research organisation and pharmaceutical partners. Together, they will focus on recruiting participants for upcoming studies scheduled to begin in Q1 2024. 

"This collaboration marks a significant step in Oncoshot's vision of creating a cancer cohort discovery platform and upcoming national-level clinical trials ecosystems and hospitals globally," said Oncoshot CEO Dr Huren Sivaraj.

Central to this partnership is the cost-free infrastructure designed to facilitate the real-time exchange of aggregated insights. This ground-breaking initiative is set to synergise their complementary strengths to enhance various clinical trial aspects throughout Japan, including feasibility assessments, participant screening, and enrolment. Japan is currently ranked as the third-largest pharmaceutical market worldwide. Notably, around 70% of clinical trials executed in Japan struggle to achieve their target patient enrolment within the designated timeframe.

Buzzreach CEO Mr Takateru Inokawa added: "We believe this partnership will positively impact clinical trials in Japan. Our shared commitment to innovation and data-driven approaches will benefit all stakeholders in healthcare research." Together, they will support end-to-end data-driven clinical trial delivery, leveraging their respective strengths.

Established in 2017, Buzzreach is a dynamic force in the healthcare technology sector, specialising in innovative solutions bridging the gap between pharmaceutical companies, medical institutions, and patients. At the recent Japan Healthcare Business Contest 2023, Buzzreach won the Excellence Award, conferred by Japan's Ministry for Economy, Trade, and Industry.

Buzzreach offers four powerful applications, each streamlining various aspects of clinical trials and patient engagement. Puzz is an information dissemination platform for pharmaceutical companies and medical institutions, allowing them to publish and share clinical trial details with consumers, prospective patients, and physicians. SMT complements this by matching patients and physicians seeking new treatment options with relevant local clinical trials, providing specific information about the trials and their locations.

Study Concierge is a patient-centric clinical trial app, assisting clinical research coordinators in notifying patients about various aspects of their participation and helping them stay on track. Lastly, StudyWorks was introduced to university hospitals and other institutions as a project management app to streamline clinical trial site operations. These apps optimise clinical trial processes, from information dissemination to patient engagement, creating a more efficient and effective drug development process.

About Buzzreach

Utilising an IT platform specialised in streamlining innovative clinical trials, Buzzreach provides region-specific subject recruitment and retention solutions, as well as efficiency-enhancing applications for clinical trial site operations. Throughout this process, Buzzreach offers support for subject recruitment and retention, along with project management assistance for clinical trial sites, all aimed at achieving goals in the shortest possible time.

Buzzreach currently operates in Japan.

About Oncoshot

Oncoshot is an innovative real-time health insights exchange platform that serves as a bridge between healthcare providers and the healthcare industry. It enables secure data exchange, connecting industry experts with crucial insights derived from real-time patient data. Oncoshot's in-premise medical LLM empowers hospitals to analyse raw healthcare data and generate actionable insights. These insights inform industry decision-making, leading to accelerated patient enrolment into clinical trials and reduced drug development costs. Ultimately, Oncoshot expedites the timely delivery of potentially life-saving therapies to patients.

For more information, visit https://www.oncoshot.com/.

SOURCE Oncoshot


These press releases may also interest you

at 19:45
TO: All persons or entities who owned Class A common stock of Pioneer Merger Corp. (in Official Liquidation) ("Pioneer") as of January 13, 2023 and the shares were redeemed (the "Class"). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal...

at 19:35
Golconda Gold Ltd. ("Golconda Gold" or the "Company") is pleased to announce the release of its financial results for the year ended December 31, 2023. All amounts are in United States dollars unless otherwise indicated. A copy of the audited...

at 19:33
TDH Holdings, Inc. ("TDH" or the "Company"), a PRC-based company that is an operator of a restaurant in the U.S., announced today its financial results for the fiscal year ended December 31, 2023. Full Year 2023 Financial Highlights:  For the...

at 19:24
NEXE Innovations Inc. ("NEXE", the "Company", "we", "us" or "our") , a leader in innovative compostable materials solutions, announces its financial results for the three-month period ended February 29, 2024 ("Q3 2024"). NEXE has a strong focus on...

at 19:22
QYOU Media Inc.,  a company operating in India and the United States producing and distributing content created by social media stars and digital content creators, is reporting financial results for the quarter and year ended December 31, 2023. ...

at 19:11
This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (the "Fund") with information regarding the sources of the distribution to be paid on April 30, 2024 and cumulative distributions paid fiscal...



News published on and distributed by: